Low-density lipoprotein cholesterol: How low can we go?

Daniel P. Sherbet, Puja Garg, Emmanouil S. Brilakis, Subhash Banerjee

Research output: Contribution to journalReview article

8 Scopus citations

Abstract

Elevated low-density lipoprotein cholesterol (LDL-C) is an established cause of cardiovascular disease and subsequent adverse events. The efficacy and safety of lowering plasma LDL-C to reduce the risk of coronary heart disease (CHD) and secondary event rates are now well established. What has not been established, however, is a plasma LDL-C lower threshold level of safety and efficacy. Here we review intensive plasma LDL-C-lowering with statins and argue that even further reductions of plasma LDL-C than current guideline targets is likely to safely reduce cardiovascular event rates. We discuss how to achieve very low levels of plasma LDL-C using both traditional and novel LDL-lowering therapies.

Original languageEnglish (US)
Pages (from-to)225-232
Number of pages8
JournalAmerican Journal of Cardiovascular Drugs
Volume13
Issue number4
DOIs
StatePublished - Aug 1 2013

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine
  • Pharmacology (medical)

Fingerprint Dive into the research topics of 'Low-density lipoprotein cholesterol: How low can we go?'. Together they form a unique fingerprint.

  • Cite this